MCL is generally considered to be an aggressive cancer, and the prognosis can vary. Historically, the median survival time was about 3 to 5 years. However, advancements in treatment options have improved outcomes for many patients. Factors influencing prognosis include:
Stage of the disease at diagnosis Patientâs age and overall health Response to initial treatment Specific genetic markers, such as the presence of certain mutations
Regular follow-up care is crucial to monitor for relapse and manage any long-term side effects of treatment.
